Status:
UNKNOWN
Research of Diagnostic Value for BMJ Infants
Lead Sponsor:
Shanghai First Maternity and Infant Hospital
Conditions:
Jaundice, Neonatal
Eligibility:
All Genders
4-42 years
Brief Summary
Breast milk jaundice (BMJ) is the main cause of neonatal hyperbilirubinemia. Excessive serum unconjugated bilirubin level will not only cause the interruption or early termination of breastfeeding, bu...
Detailed Description
This project is a single-center, prospective nested case-control study to investigate feasibility and practical value of diagnostic markers in infants with BMJ. According to the admission criteria, 1...
Eligibility Criteria
Inclusion
- All the following conditions must be met
- Term newborns admitted to hospital with "neonatal hyperbilirubinemia"
- Exclusive breastfeeding or mainly breastfeeding
- Exclude perinatal infection, G-6P-D deficiency, homoimmune hemolysis, polycythemia, scalp hematoma, intracranial hemorrhage, cholestasis, hypoglycemia, hypothyroidism, hypothermia, neonatal asphyxia, fetus Pathological jaundice factors such as delayed stool excretion.
Exclusion
- As long as any one of the following conditions should be excluded
- During the follow-up period, breastfeeding was terminated or the daily milk powder intake exceeded 200 ml.
- Other pathological jaundice was diagnosed during the follow-up period.
- Take probiotics during the sampling period.
- The guardian asked to withdraw from the study halfway.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04527536
Start Date
October 1 2020
End Date
September 30 2022
Last Update
August 26 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.